Bellevue Life Sciences Acquisition Corp.
BLAC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | 0.01 | -0.00 | -0.01 |
| FCF Yield | -23.35% | -0.32% | -0.47% | -0.97% |
| EV / EBITDA | 0.00 | -2.29 | -4.27 | -24.89 |
| Quality | ||||
| ROIC | -1.67% | -3.08% | -1.81% | 59.28% |
| Gross Margin | 41.69% | 2.89% | 22.16% | 0.00% |
| Cash Conversion Ratio | -0.51 | 0.00 | 0.01 | 0.25 |
| Growth | ||||
| Revenue 3-Year CAGR | 1,361,534.42% | 1,237,764.21% | 912,989.37% | -100.00% |
| Free Cash Flow Growth | -7,097.34% | 31.68% | 87.26% | -121.66% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.29 | 0.35 | -0.79 |
| Interest Coverage | -86.71 | -141.60 | -177.93 | 49.85 |
| Efficiency | ||||
| Inventory Turnover | 1.98 | 5.55 | 0.80 | 0.00 |
| Cash Conversion Cycle | 45.51 | 16.23 | 111.88 | 0.00 |